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Padova University Hospital, ItalySummary conventional parameters are not enough to give a thoroughThe outcome of liver transplantation is usually reported in terms
of graft and patient survival, medical and surgical complications,
and quality of life, but when it comes to transplanted adolescents
such conventional parameters are unable to give a full account of
their life with a new liver, and their transition from adolescence
to adulthood is a time when they are particularly vulnerable.
Adolescents with liver transplants have excellent survival rates,
over 80% of them surviving more than 10 years. Graft loss is most
often associated with complications such as chronic rejection,
hepatic artery thrombosis, and biliary complications. Calcineurin
inhibitors may have various side effects, including hypertension
and nephrotoxicity. Liver-transplanted adolescents are also
exposed to viral infections, among which Epstein-Barr virus is
very common and associated with the onset of post-transplant
lymphoproliferative disorders. Growth retardation may also be
an issue in some liver transplant recipients.
Future studies will determine the best way to assess the func-
tional immune status of adolescents with a transplanted liver
with a view to ensuring the best treatment to induce tolerance
without the complications of excessive immunosuppression.
Schooling may be disrupted due to adolescent transplant recipi-
ents’ poor adherence. Non-adherence is associated with a poor
medical outcome. Both physical and psychosocial functioning is
reportedly lower among young liver transplant recipients than
in the general population.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Although the annual number of new paediatric liver transplant
recipients has remained stable in recent decades, these patients
undergo a transition to adolescence and then adulthood, there-
fore the number of long-term survivors has grown [1] thanks to
the excellent survival rates achieved these days. The outcome
of liver transplantation is usually reported in terms of graft and
patient survival, medical, and surgical complications, and quality
of life, but for many transplanted children and adolescents theseJournal of Hepatology 20
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The transition from childhood to adolescence and adulthood
may be very complicated in liver-transplanted patients. Numer-
ous studies have been published on paediatric transplant recipi-
ents, but there is still a paucity of information on the long-term
follow-up of adolescents.
The challenges to face in the setting of liver transplantation in
adolescents concern the patients’ long-term liver function (which
should be evaluated prospectively) and their risk of developing
medical complications, as well as issues relating to their return
to normal life, which apparently nearly always remains incom-
plete in spheres relating to their formal education, leisure and
sports activities, occupations, sex life, and relationships with
family, friends, and peers, at school and at work
Key Points
• Liver transplantation in adolescent recipients has 
excellent survival rates; however, both physical and 
psychosocial functions are lower compared to the 
general population
• The transition from adolescence to adulthood is a period 
when they are particularly vulnerable, and it carries 
a high risk of non-adherence to immunosuppressive 
therapy
• Immunosuppression-related side effects are the major 
cause of non-adherence, together with problematic 
relationship between adolescent patients and their family
• A proper assessment of the immune status of liver 
transplanted adolescents would allow clinicians to modify 
the immunosuppressive therapy, reducing side effects 
and promoting tolerance
In seeking strategies to improve transplanted adolescents’
adherence to the medication they require, we need to consider
how they change as they grow up, the role of their parents, their
demand for independence, and the consequences of non-adher-
ence on their health.Personal experience at the ‘‘Padova Multivisceral Transplant
Unit’’
My personal experience with young liver transplant recipients
over the past 20 years, as a transplant hepatologist, is based on12 vol. 56 j 714–722
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13 cases (2 females and 11 males), 5 of them aged 13–19 years,
the other 8 over 20 years of age at the time of their transplant.
Nine of these patients are still alive and all but one are well,
the exception being a patient who developed pontine myelinoly-
sis after the transplant and who is still dyslexic and aggressive
10 years afterwards. Among the 4 deaths, one boy died 3 months
after the transplant as a result of severe neurological complica-
tions due to Wilson’s disease, one died a few days after undergo-
ing retransplantation for cholestatic liver disease, one died
10 days after retransplantation for liver failure, and one died a
month after retransplantation as a result of vascular complica-
tions occurring in the ﬁrst graft 17 days after the ﬁrst transplant
procedure.
The Multivisceral Transplant Unit in Padova has had a speciﬁc
task force, with trained educators and a psychologist, in place for
7 years to assess adherence problems and drive interventional
processes to improve the rate of adherence in liver-transplanted
patients.
Looking at the period of transition to adulthood, 6 of our 8
patients who are still alive were diagnosed with poor adherence,
which related to lifestyle (one smoked, two drank alcohol), med-
ical prescriptions (three failed to submit to the necessary blood
tests, one stopped taking immunosuppressants, one did not
attend the outpatient clinic). One patient had psychological prob-
lems, and one was non-adherent in more than one aspect.
Our psychologist reported that the main concern expressed by
young liver transplant recipients was that the medical staff pre-
scribed too many tests. Adolescents often visit web sites to see
if there are any alternatives to immunosuppressants, and the
majority are frightened of their doctor (which is the only reason
why they take their prescribed drugs). A feeling they have in
common is of an intimate battle between their awareness that
they have a chronic health problem for which they have to follow
their doctor’s advice and their strong inclination to be and behave
just like other people of their age. They disregard their doctor’s
ban on alcoholic beverages when they are amongst friends who
are drinking socially. They are concerned about their appearance,
their peer status, their physical performance and body image.
Health-related quality of life is therefore one of the major fac-
tors potentially inﬂuencing adherence and it has an impact on
short- and long-term outcome. This is clearly demonstrated by
the case of a young girl transplanted at our unit, who decided not
to take her immunosuppressantswhen a problemarose in her love
life. Though she was physically well, she came to our clinic, where
blood tests indicated AST and ALT levels of nearly 1000 and 800
IU/L, respectively, with undetectable tacrolimus levels. She was
immediately given 1 g ofmethylprednisolone iv and her blood test
results improved the next day (AST 600 IU/L, ALT 400 IU/L). After
her acute rejection episode had been treated and her tacrolimus
doses had been increased, within a week her transaminases were
within normal range. If this patient had not come to us, she could
well have experienced a more intractable acute rejection or, more
likely, an irreversible chronic rejection, within a fewweeks. It does
not bear thinking about the risk of her needing a new graft, given
the 11% mortality on the waiting list at our unit in 2010.Managing adolescents with chronic liver disease
Dealing with end-stage liver disease in adolescents poses a chal-
lenge for hepatologists and gastroenterologists. Adolescents
experience many of the same complications of cirrhosis as adults,Journal of Hepatology 201e.g. ascites, spontaneous bacterial peritonitis, encephalopathy,
and oesophageal bleeding, but there are speciﬁc issues involved
when it comes to managing such complications in adolescents.
Some of these complications, such as splenomegaly, can nega-
tively affect the patient’s quality of life as a result of physical
restrictions and body image problems. Amenorrhoea, oligom-
enorrhoea or irregular episodes of metrorrhagia are common in
young female patients, secondary to chronic anovulation; this is
not always related to the duration or severity of a girl’s liver dis-
ease, and it may stem from hypothalamic–pituitary dysfunction
occurring at some stage [2,3].
The aetiology of adolescent liver disease differs from that of
adults. Adolescent patients with Alagille syndrome may have car-
diac or renal disease; patients with storage diseases may have
muscle and neuron involvement; and adolescents with autoim-
mune hepatitis or Wilson’s disease can show the signs and symp-
toms of cirrhosis [4].
Malnutrition is another crucial issue at an age when patients
are still growing. Then there is the number of drugs needed to
prevent or treat the complications of end-stage liver disease,
which might interfere with an adolescent’s routine, having a con-
siderable psychological impact on their daily life. Advising young
patients against certain lifestyle choices, especially smoking and
alcohol, is often a problem too. As concerns the latter, a wide-
spread phenomenon amongst young people is binge drinking,
which can begin at around 13 years old and tends to increase
during adolescence, peaking in young adults (between 18 and
22 years of age). Adolescents who indulge in such excessive alco-
hol intake may have difﬁculties achieving the goals typical of the
transition from adolescence to young adulthood. The manage-
ment of adolescents with end-stage liver disease consequently
warrants careful attention. Many physicians are well aware that
young people with particular health care needs want their inde-
pendence, good health, friends and jobs, just like anyone else of
their age [5]. A study conducted to examine the process of tran-
sition from paediatric to adult health care in young adults with
special health care needs suggested that these adolescents need
to stop dealing with the world of paediatrics, but neither they
nor their families are prepared to cope with the adult health care
system [6]. This transition has been described as a multi-faceted
process that demands communication skills, parenting, self-
advocacy and vocation [7].Liver transplantation
Waiting list
Data on patients on the waiting list for liver transplantation are
usually reported for the paediatric population as a whole, with-
out distinguishing adolescents from children. According to US
data, the number of paediatric patients on the waiting list for a
liver transplant rose from 1996 to 2001, then declined up until
2005, when the PELD scoring system was introduced. There were
462 paediatric patients on the waiting list for a new liver in the
US in 2005, and 136 of them (29%) were adolescents (11 years
old or more) [8].
Immunosuppression and its complications
In a report dating from 2005, 92% of paediatric liver transplant
recipients were reportedly taking tacrolimus, while 4% were on2 vol. 56 j 714–722 715
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cyclosporine and, although steroid-free protocols were recom-
mended, 84% of liver-transplanted young people were discharged
on maintenance corticosteroids [8]. The use of azathioprine
dropped from 50% in 1997 to 6.2% in 2004, while the use of myco-
phenolate mofetil rose from 3.9% to 28% during the same period
[9].
Tacrolimus remains the immunosuppressant most commonly
used in adolescents, although it is well known that calcineurin
inhibitors may cause various side effects, including hypertension
and nephrotoxicity.
In the long term, young liver transplant recipients had stage 3
chronic renal disease, 5, 7, 10, and 15 years after the transplant in
13%, 21%, 31%, and 33% of cases, respectively. Cyclosporine A
trough levels were a signiﬁcant time-dependent factor in the
regression model; when time was removed from the model, pro-
teinuria became the most signiﬁcant factor [10].
Among 117 young patients who survived more than 3 years
after receiving a liver transplant, kidney function (as determined
by measuring the glomerular ﬁltration rate [mGFR]) was
impaired in 32% of cases. The mGFR a year after the transplant,
cyclosporine and the time elapsing since the transplant were all
signiﬁcant in the univariate analysis, and the mGFR and cyclo-
sporine remained signiﬁcant when the multiple logistic regres-
sion model was used [11]. When we are dealing with children
and adolescents, this means that patients might live long enough
into adulthood for their renal dysfunction to develop into end-
stage disease necessitating a kidney transplant.
Efforts are being made to reduce these young people’s long-
term exposure to calcineurin inhibitors by means of minimiza-
tion protocols, switching them to mycophenolate mofetil or
sirolimus.
Mycophenolate mofetil has proved safe and effective in liver-
transplanted children with renal dysfunction. If these patients
were taking cyclosporine or tacrolimus as their main immuno-
suppressant, mycophenolate mofetil enabled a reduction in the
dose of calcineurin inhibitors (CNI), and even their completeTable 1. Studies on calcineurin inhibitor minimization or withdrawal associated w
recipients.
Author, (year),
[Ref.]
Number
of patients
Age at 
conversion
Years from LT
to conversion
IS regimen 
before MMF
IS
af
Chardot et al., 
(2001), [13]
19 n.r. 0.36 CsA ± Ster ± Aza
Tac ± Ster
M
Nobili et al., 
(2003), [16]
8 13 At least 5 CsA/Tac M
Aw et al.,
(2001), [12]
14 n.r. 4.75 CsA ± Ster ± Aza
Tac ± Ster
M
M
IS
Ferraris et al., 
(2004), [15]
11 12.5 CsA + Ster M
Evans et al., 
(2005), [14]
48 11.2 4 CsA ± Ster ± Aza
Tac + Ster
M
M
M
Tannuri et al., 
(2007), [17]
11 7 4 CsA/Tac ± Ster M
⁄3/19 patients with renal dysfunction; ⁄⁄patient who received auxiliary graft for acute liv
at 24 months vs. baseline.
CNI, calcineurin inhibitors; CsA, cyclosporine A; Tac, tacrolimus; MMF, mycophenolate m
rejection; CCR: chronic cellular rejection.
716 Journal of Hepatology 201withdrawal in some cases, with a concomitant improvement in
renal function [12–17]. A beneﬁcial effect was also shown in
the 62% of patients whose liver dysfunction was due to acute cel-
lular rejection (Table 1). Young recipients are at risk of rejection if
their immunosuppression is reduced, so it has been recom-
mended that additional steroids be administered during their
transition to mycophenolate mofetil [14].
Another CNI-sparing approach is based on the use of sirolimus
associated with the reduction or complete withdrawal of CNI.
Data on sirolimus in young liver-transplanted patients are scant,
however. The results of studies exploring CNI minimization asso-
ciated with the addition of sirolimus have shown that the latter
has a positive effect on renal function [18,19] and liver function
[18], and it enables steroids to be discontinued [20]. In one of
these studies [19], however, 9/9 patients developed high serum
cholesterol levels, and sirolimus was discontinued in 3/9 patients
(33.3%). Experience of completely replacing CNI with sirolimus is
based on only one study [21]. The authors studied 32 paediatric
liver-transplanted patients with tacrolimus-related side effects
who were all converted to sirolimus: at the end of the follow-
up, 78% (n = 30) had successfully completed the conversion,
while 22% (n = 9) returned to a tacrolimus-based regimen due
to serious adverse events; and two of these latter 9 patients expe-
rienced an acute rejection (Table 2).
Tacrolimus may also be associated with cardiac hypertrophy.
In a study on 18 young liver transplant recipients with no history
of cardiac disease, who were all normotensive before their trans-
plant, cardiac function was grossly preserved but the markers of
early cardiac damage rose to higher levels than in healthy, age-
matched controls [22]. In the general population, even young
people are at risk of developing coronary and aortic atherosclero-
sis if they have risk factors such as a high body mass index, high
cholesterol levels or high systolic, and diastolic blood pressure
levels [23].
Liver-transplanted adolescents are exposed to viral infections.
Epstein-Barr virus (EBV) is very common in the paediatric liverith the addition of mycophenolate mofetil (MMF) in young liver transplant
 regimen 
ter MMF
Renal function 
improvement
Liver function 
improvement
Rejection and 
other adverse events
MF + CNI low dose Stable in 2/3*
40% in 1/3*
62% Other 6/19
MF + CNI low dose 100% at 6 mo - ACR 0
CCR 0
Other 1/8
MF + CNI low dose
MF monotherapy 
 off**
92% at 12 mo - ACR 3/14
CCR 0
Other 6/14
MF + CNI low dose p <0.0002§
p <0.007#
- ACR 0
CCR 0
Other 0
MF + Ster
MF monotherapy
MF + CNI low dose
92% at 2 mo - ACR 2/48
CCR 2/48
Other 7/48
MF + CNI low dose 82% at 24 mo - ACR 0
CCR 0
Other: 2/11
er failure. §In plasma creatinine at 24 months vs. baseline; #in creatinine clearance
ofetil; IS immunosuppression; Ster, steroids; n.r., not reported; ACR, acute cellular
2 vol. 56 j 714–722
Table 2. Studies on calcineurin inhibitor minimization or withdrawal associated with the addition of sirolimus (SRL) in young liver transplant recipients.
Author,
(year), [Ref.]
Number
of patients
Age Time 
from LT 
to SRL 
Initial IS regimen 
IS regimen
Renal function 
improvement
Liver function 
improvement
Rejection and 
other complications
Sindhi et al.,
(2002), [20]
15 n.r. n.r. Tac low dose + Ster + SRL
Tac low dose + SRL
Tac low dose + SRL
SRL monotherapy
n.r. - ACR: 1/6
ACR: 3/9
Markiewicz et al.,
(2003), [19]
9 5.2-21.8 1.12 yr Tac/CsA + Ster 
CsA + Ster + MMF/Aza 
CNI low dose + SRL
SRL monotherapy
GFR improved by 41% 2/2 ACR: 0
CCR: 0
Casas-Melley 
et al., (2004), [18]
38 8.6 n.r. Tac-based IS Tac low dose + SRL
SRL monotherapy
GFR improved by 25% p = 0.02*
p = 0.59**
ACR
CCR
Other: 20/38***
Sindhi et al.,
(2005), [21]
39° n.r. 95 mo Tac
SRL
SRL monotherapy Improvement in 8/14 - ACR: 2/39#
Other: 7/39#
Modification of
⁄AST at vs. baseline; ⁄⁄ALT at vs. baseline; ⁄⁄⁄Leading SRL withdrawal. In 13/20 SRL was restarted. 36 liver transplants, 1 small intestine transplant alone, 2 multivisceral
transplants. #All 9 patients were reconverted to tacrolimus.
CNI, calcineurin inhibitors; CsA, cyclosporine A; Tac, tacrolimus; MMF, mycophenolate mofetil; IS immunosuppression; Ster, steroids; n.r., not reported; ACR, acute cellular
rejection; CCR: chronic cellular rejection.
JOURNAL OF HEPATOLOGYtransplant population and this infection is associated with the
onset of post-transplant lymphoproliferative disorders (PTLDs).
The incidence of PTLDs was reportedly 16% before a protocol
for EBV monitoring and the pre-emptive modulation of immuno-
suppression was adopted, which reduced their incidence to 2%,
according to one single-centre experience [24].
Another concern, particularly when it comes to children, lies
in that some drugs carry a risk of ototoxicity, potentially exposing
younger recipients to hearing impairments. In a review of 74 chil-
dren who underwent liver transplantation, and whose hearing
was assessed at discharge, it was reported that 15% of the sample
experienced sensorineural hearing loss, although it was severe to
profound in only a few of them [25].
The potential interference of immunosuppression with an
adolescent’s psychosocial development is also something to bear
in mind, though the type of immunosuppression administered is
generally believed to have no inﬂuence on the main aspects of
cognitive function [26].
Future studies will hopefully establish how best to assess the
functional immune status of adolescent transplant recipients in
order to achieve the best results while avoiding the complications
of excessive immunosuppression [27].
Risk factors for graft loss
An interesting histopathological study was conducted on 158
asymptomatic children: 113 liver biopsies were performed at
1 year, 135 at 5 years, and 64 at 10 years after their transplant.
A normal or near-normal histology was reported in 68% of the
cases who underwent liver biopsy at 1 year, in 45% of those
tested at 5 years, and in 31% of the biopsies obtained 10 years
after the transplant procedure. The rates of chronic hepatitis
increased with time, however, from 22% to 43% to 64% at 1, 5,
and 10 years, respectively. Fifteen percent of the young recipients
had cirrhosis within a decade of their transplant surgery, and
autoantibody positivity was the only predictor of this condition,
which supports the conviction that liver ﬁbrosis is a consequence
of immune-mediated injury [28].
In a study performed in young patients transplanted for
biliary atresia, liver histology was abnormal in 73% of long-term
survivors, due mainly to chronic rejection and centrilobular
ﬁbrosis [29].Journal of Hepatology 201Data from the SPLIT (Studies on Paediatric Liver Transplan-
tation) database indicate that graft loss after the ﬁrst year was
caused by acute rejection in 11% of cases and by chronic rejec-
tion in 37%; the sequelae of technical complications were
responsible for another 20% of late graft losses (11% were cases
of hepatic artery thrombosis, and 9% were biliary complica-
tions). When the authors performed a multivariate analysis,
they found that liver transplantation for tumour, steroid-
resistant rejection, re-operation within the ﬁrst month, and
more than 5 hospital admissions during the ﬁrst post-opera-
tive year were independently associated with late graft loss
[30].
Children with non-cholestatic cirrhosis carry the same short-
term risk but a higher risk of long-term graft failure than in cases
of cholestatic cirrhosis. Younger age is associated with a greater
risk of graft loss. Health status at the time of the transplant and
the source and type of the graft predicted short-term, but not
long-term graft loss [9].
The higher incidence of graft loss in adolescents has consis-
tently been linked to their non-adherence to their prescribed
medication [31,32], considered a potential explanation for acute
rejection during their transition to adulthood, but few studies
have actually examined the changes in the patterns of adolescent
adherence during this time of their life [33].
The graft loss rate does not seem to be higher during the tran-
sition from adolescence to adulthood [34]; instead, a steady dete-
rioration begins already in adolescence and continues into young
adulthood. It may be that adherence deteriorates during the tran-
sition period, but its fallout on graft function is not immediately
apparent [32].
A clinical program to improve adherence to medical prescrip-
tions was applied to liver-transplanted children and adolescents,
attempting to identify non-adherent patients by testing their
tacrolimus levels in the blood, and then increasing the required
frequency of visits to the clinic for non-adherent recipients. Using
this approach, the number of patients with high alanine amino-
transferase levels (i.e. 100 or more) decreased signiﬁcantly, sug-
gesting that speciﬁc measures can help improve outcome,
although larger studies are needed to conﬁrm the efﬁcacy of this
approach [35].
In another retrospective cohort study on 101 paediatric liver
transplant recipients taking tacrolimus, biopsy-proven acute2 vol. 56 j 714–722 717
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rejection was considered the primary outcome. The variables
judged capable of predicting non-adherence were the standard
deviation of the blood levels of tacrolimus (determined on the
strength of at least four tests for each patient during the study
period), mean tacrolimus levels, age, and type of insurance. The
authors reported that some recipients had a marked variability
in their tacrolimus levels and concluded that such variations
were associated with a higher risk of late graft rejection. They
recommended psychosocial and behavioural measures to prevent
late graft dysfunction in such patients [36].
Evidence of some non-adherent liver-transplanted patients
being able to discontinue their immunosuppression regimen
without developing any clinical complications has raised the
need to study the possibility of inducing tolerance in young
patients. On the other hand, although inducing tolerance is
important, it is far from easy to extrapolate data on adolescents
from the few published reports, which usually combine both
adult and paediatric populations.
In a recent review on operational tolerance after liver trans-
plantation [37], studies performed at the Pittsburgh Transplant
Center reported a success rate of 29% amongst 95 patients, who
were a mean 11.8 years old when they were weaned from immu-
nosuppression [38–48]; the follow-up, after immunosuppression
had been withdrawn, was 180 months. In another two case
reports [49,50], immunosuppression was successfully withdrawn
from recipients 7 [50] to 9 [49] years of age, with a follow-up of
46 and 30 months, respectively.
There is no doubt that inducing tolerance or tailoring immu-
nosuppressive therapy would be beneﬁcial in the management
of young liver-transplanted patients, as it might enable their
long-term immunosuppression to be reduced, thus avoiding the
onset of immunosuppression-related side effects [51]. The identi-
ﬁcation of speciﬁc and robust biomarkers capable of predicting
operational tolerance is fundamental to any strategies to mini-
mise or withdraw immunosuppression without exposing recipi-
ents to a high risk of acute and chronic rejection, or to atypical
features of immune-related liver dysfunction [52]. Properly-
designed prospective trials are needed to reproduce and validate
the results of exploratory retrospective studies.
Adherence
Non-adherence to medical prescriptions is associated with a poor
medical outcome in adolescents after liver transplantation [53].
During the transition from paediatric age to adulthood, transplant
recipients seem to becomeparticularly vulnerable to this problem.
A retrospective analysis was performed on 111 adolescent
patients aged 12–21 years, 45% of whom were non-adherent:
20% did not attend the clinic for scheduled visits and 10.9% did
not complete their prescribed laboratory tests. Poor adherence
was associated with single parent status, older age, and more
years elapsing since the transplant. These ﬁndings conﬁrmed that
non-adherence is a prevalent problem among adolescents and
that strict monitoring of their adherence to post-transplant care
is needed to improve their long-term survival rates and quality
of life [54].
The medical records of 14 adolescents were reviewed and
their adherence and corresponding medical outcomes were com-
pared before and after their transition to adulthood: their adher-
ence to medication, as measured from their tacrolimus levels in
the blood, decreased signiﬁcantly after said transition [33].718 Journal of Hepatology 201In my opinion, a speciﬁc programme of information and edu-
cation dedicated to adolescent transplant recipients should be
made available at all transplant centres. There are reports of dif-
ferent experiences around the world. The Pediatric Committee of
the American Society of Transplantation recommended that ado-
lescents have a dedicated coordinator responsible for their health
care [55], who can take action to facilitate their transition. At
other centres, this role is assigned to nurse practitioners [56].
We know that non-adherence to medical regimens is associ-
ated with more medical complications, graft rejection, mortality,
and health care usage rates [1], with the related use of the ﬁnan-
cial resources reserved for transplantation medicine. Poor adher-
ence to medication regimens is responsible for 30–70% of all
medication-related hospital admissions in the United States, with
a dramatic impact on the costs of the health care system, calcu-
lated at around $100 billion a year [57–59].
Growth
In children, growth retardation may be a consequence of end-
stage liver disease [60] and liver transplantation unfortunately
does not always assure a normal growth. In a retrospective study,
catch-up growth was reported in 37–47% of 221 young recipients
at any given time point after receiving a transplant. Factors in
favour of a normal growth were ﬁrst-time transplants, a more
severe growth retardation at the time of the transplant, younger
age, and lower doses of prednisolone [61].
Once they have achieved a normal growth, it is crucial for
liver-transplanted adolescents to engage in some physical activ-
ity to avoid them gaining unnecessary weight. Obesity is associ-
ated with a higher long-term mortality, mostly as a result of
cardiovascular events [62].
Cognitive function and schooling
In a study on children with biliary atresia 10 years after liver
transplantation, 63 out of 80 young recipients attended school
normally and 69% of them had a normal school performance [6].
A younger age at the time of the transplant, a shorter duration
of the liver disease and a more advanced stage of physical devel-
opment before liver transplantation were reportedly associated
with a better prognosis for young liver transplant recipients’
mental development [63]. The liver-transplanted young people’s
cognitive abilities were assessed using the 3 subscales of the
Kaufman Assessment Battery for Children (the sequential pro-
cessing scale, the simultaneous processing scale, and the achieve-
ment scale b) [64] and the impression was that, when liver
transplant recipients were already adolescents when the liver
disease prompting transplantation developed, they probably
experienced a more severe disruption of their daily routine, social
contacts, and personal life [26]. Young liver transplant recipients
usually scored below the mean for the general population in
terms of cognitive tools, and this was particularly noticeable on
the subscales for withdrawal, thought problems and attention
problems. Behavioural problems were associated with a worse
cognitive performance in 25 liver-transplanted children who
were 8.5 ± 2.8 years old at the time of their assessment, and their
cognitive functioning problems were associated with medical
complications [64].
A low cognitive status may also coincide with emotional difﬁ-
culties. A study performed on 21 young liver transplant recipients2 vol. 56 j 714–722
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(4–16.9 years old) aimed to evaluate their cognitive and emo-
tional development after their transplantation procedure. Cogni-
tive status was found lower than the expected normal values in
the transplanted patients, and the results were worse than
expected. Half of this sample of patients also had emotional prob-
lems [65].
Schooling may be negatively affected by poor adherence to
prescribed medication. In a recent study, when data on adherence
were pooled together, it emerged that at least 3 in 4 adolescent
liver transplant recipients were non-adherent on at least one
measure of adherence. It was clear that the group of non-adher-
ent recipients experienced more severe limitations on their
school activities and their mental health suffered more; they also
had a worse perception of their health and a lower self-esteem
and family cohesion [66].
School performance is an important aspect of functional out-
comes in the adolescent population. An interesting longitudinal
survey on school attendance, performance, and educational out-
comes (including the need for targeted educational programs)
was recently published [67], performed on 823 liver transplant
recipients whose median age at the time of their transplant sur-
gery ranged from months to 17.8 years. These 823 cases came
from 39 liver transplant centres in the US. A third of the children
and adolescents had missed more than 10 days of school a year,
and absences were higher for older recipients and for shorter
times elapsing since liver transplantation. More than a third of
the sample needed extra teaching and one in ﬁve had repeated
a school year. The type of immunosuppression taken 6 months
after the transplant, CMV infection and the teaching services used
before the transplant were the main factors associated with the
need for special support. The most striking predictor was the
pre-transplant need for extra teaching (OR 22.46), suggesting
that most neurocognitive impairments seen after transplantation
originated beforehand [66]. An editorial on this topic published in
the same journal as the survey emphasized that the article looked
at functional outcomes, as well as surgical and biological results,
in survivors of paediatric liver transplantation, and congratulated
the authors on their contribution to moving the ﬁeld towards a
broader approach to outcome assessment [68].
A multicentre study on cognitive and academic outcomes was
recently performed in 5–7 year-old children two years after their
transplantation: it conﬁrmed that these young liver transplant
recipients performed signiﬁcantly below test norms in terms of
their intelligence quotient and achievement measures, and 26%
had mild-to-moderate IQ delay, whereas the normally expected
rate is 14%. Four percent had severe mental delays and learning
difﬁculties [69].
Quality of life
Both physical and psychosocial functioning is reportedly lower in
young liver transplant recipients than in the general population.
A study was performed to assess health-related quality of life
and psychosocial functioning among 38 young liver transplant
recipients, including adolescents. The health status measurement
included the frequency of hospital admissions, the need for liver
biopsies due to abnormal liver function test ﬁndings, rejection
episodes and graft function. Attendance at the clinic and standard
deviations of consecutive tacrolimus blood levels were also eval-
uated as a measure of adherence. Non-adherence correlated with
a lower physical health-related quality of life, more limitations inJournal of Hepatology 201social and school activities due to emotional problems, parental
distress and loss of family cohesion, as well as the frequency
and duration of hospital stays, liver biopsies and episodes of
acute rejection. It appears that young recipients with this difﬁcult
background should be identiﬁed and carefully followed up to
reduce the risk of poor compliance with immunosuppression
and the consequent risk of rejection and graft loss [70].
The debate on the different health perceptions of adolescents
is therefore prompted by various ﬁndings. In a sample of 51 ado-
lescent liver transplant recipients [71], it was seen that their gen-
eral health was worse, but their physical health was similar to
that of the general population. Caregivers have reported a nega-
tive emotional impact of their child’s health issues on themselves
and on the family’s activities [71], indicating that caregivers may
be able to provide adolescents with psychological support, but
they are inadequate when the problems are health-related.
An interesting study was performed on 55 adolescents aged
12–18 years, in which the authors evaluated allograft morbidity,
psychological and family-related variables, measured by means
of questionnaires. Adolescents had a lower health-related quality
of life in all domains except for role/social behaviour and family
cohesion, by comparison with the general population. They expe-
rienced 18 symptoms relating to immunosuppression and 75% of
them had one or more chronic illnesses relating to their immuno-
suppression. Twenty-two percent of them reported a history of
emotional difﬁculties. When the data were assessed by regres-
sion analysis, the factors associated with quality of life were
age at transplantation, secondary illnesses, symptom distress,
headaches, history of emotional difﬁculties, self-esteem, and fam-
ily conﬂicts [72]. It therefore seems that we should look at
numerous factors in adolescents, such as the presence of other
diseases and medical complications due to immunosuppression,
as well as assessing family relations before and after liver trans-
plantation. If an adolescent apparently had no psychosocial prob-
lems before undergoing transplantation, that does not necessarily
mean they do not risk developing such problems afterwards,
given the many risk factors involved. Transplant follow-up sur-
veillance programs should therefore be tailored to adolescent
liver transplant recipients, whereas we have all often considered
the transition to adulthood as a sort of biologically-driven event
common to all adolescents, without adequately considering how
particularly difﬁcult this transition can be for transplanted
adolescents.
It is rather difﬁcult to report on the adjustment of adolescents
reaching adulthood. One study based on telephone interviews
conducted with 118 liver transplant recipients aged 17–33 years
found that 76% of them judged their quality of life to be good or
very good, 65% of them were attending school (though 27/75
were 2 years or more behind their age-appropriate school year),
26 had a job, and 15 were unemployed. Poor compliance with
medication was reported by 52 patients, corresponding to 45%
of the whole group. Anxiety, loneliness and negative thoughts
were reported by 53%, 84%, and 47% of the young adults inter-
viewed. Among them, 11% were in the care of psychologists or
psychiatrists [73]. In early adulthood these patients appear to
be very vulnerable and, here again, they represent a group that
should be offered a tailored follow-up.
We should also add that adolescents usually refer an improve-
ment in theirhealth-relatedqualityof life after their transplant and
the impairment they experience after transplantation is less severe
than in adolescents with other chronic illnesses [74]. This was2 vol. 56 j 714–722 719
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Fig. 1. European Liver Transplant Registry data for patient and graft survival
rates in patients between 2 and 15 years old of age (01/1988–06/2009) [78].
C
um
ul
at
iv
e 
su
rv
iv
al
Cholestatic
Acute hepatic
necrosis
Cirrhosis
Metabolic
Other
4620 patients
log-rank p <0.001 
Months after liver transplantation
0 24 36 48 60 72 84 96 108 12012
1.0
0.8
0.6
0.4
0.2
Fig. 2. European Liver Transplant Registry data for patient survival rates in
patients between 2 and 15 years of age by aetiology of liver disease (01/1988–
06/2009) [78]. (4620 patients, log-rank p <0.001).
Frontiers in Liver Transplantationconﬁrmedwhen a cross-sectional study on quality of life was con-
ducted on a population of 2–18 year-olds that included liver trans-
plant recipients, healthy children and paediatric patients with
cancer receiving chemotherapy and/or radiation: the transplant
patients reported better physical functioning than the patients
with cancer, but similar social and academic functioning [75].
Patient survival
Survival rates after paediatric transplantation are excellent, since
more than 80% of recipients will survive more than 10 years. Pol-
ysplenia syndrome, UNOS status at transplant, donor age and
perioperative complications were the prognostic factors for death
identiﬁed in a study performed a few years ago [29].
Outcomes based on 872 paediatric patients from the SPLIT
registry who survived the ﬁrst year after transplant surgery con-
ﬁrmed that 5-year graft and patient survival rates were 89.2% and
94.2%, respectively [30].
Data from the OPTN and SRTR in the United States indicate
that 9% of the whole liver transplant population in 2007 was rep-
resented by recipients under 18 years of age, and their survival
rates were 90% at 1 year, 82% at 5 years, and 80% at 10 years
[76,77].
The European Liver Transplant Registry (ELTR) reported that
between 1988 and 2009 the 1-, 3-, 5-, and 10-year survival rates
for children between 2 and 15 years of age were 74%, 70%, 68%,
and 62% for the graft, and 83%, 80%, 77%, and 75% for the patient
(Fig. 1).
Considering the main indications for transplantation, 10-year
patient survival was 80% for cholestatic and metabolic diseases,
and lower for cirrhosis (70%), and acute liver failure (67%)
(Fig. 2) [78].
Malignancies, infections, multiple organ failure and PTLDs
accounted for nearly 62% of late deaths after transplantation
according to a SPLIT database analysis. Late mortality was more
common in patients transplanted for fulminant hepatic failure
and malignancies, and the risk of dying was higher for patients
who were below the mean for weight at the time of their trans-
plant surgery [30].
When liver transplantation was proposed as the treatment of
choice for hepatoblastoma, it was demonstrated in a small series
of 7 young recipients that the overall survival rate at 10 years was
85%, much higher than among 5 children who underwent liver720 Journal of Hepatology 201transplantation as a rescue procedure, following partial hepatec-
tomy [79].
The survival rate after late re-transplantation was reported to
be 63.3% and causes of late graft loss were infections (21.2%),
PTLDs (21.2%), chronic rejection (17%), biliary complications
(14.8%), and recurrent malignancies (8.5%) [80].Best practice and dreams of developing speciﬁc adolescent
services
Adolescent liver transplant recipients represent a particular sub-
group of transplanted patients since their needs can differ signif-
icantly from those of children and adult patients undergoing the
same procedure.
Adolescence is a complex transitional process ‘‘per se’’. Devel-
oping a chronic medical condition such as liver cirrhosis, which
requires hospitalization, speciﬁc treatments and, sometimes,
even liver transplantation, in adolescence can be an additional,
serious complication. All adolescents’ concerns about their phys-
ical appearance, their need to become independent, their rela-
tionships with parents and friends, can be intensiﬁed by a
chronic illness or an operation such as liver transplantation,
which dramatically changes their life perspective.
Speciﬁc programs for adolescents should therefore be avail-
able at all transplant centres, especially during the transition
from adolescence to adulthood. These programs should be
based on multidisciplinary measures developed by professional
educators, supported by psychologists and coordinated by
transplant physicians. One of the ﬁrst aims should be to
enhance the patients’ knowledge of their chronic liver disease
and the liver transplantation process. Patients should be prop-
erly informed about the need for medication, including all
potential side effects of immunosuppressants, and they should
also be encouraged to share all their concerns about their body
changes, especially when related to their medical treatment.
Their behavioural skills in using drugs, and their ability to
identify and report problems related to their condition should
be reinforced, together with their ability to understand how
to maintain a suitable lifestyle.
Proper education for adolescent organ transplant recipients
could have an essential role in improving their outcome after a2 vol. 56 j 714–722
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liver transplantation by increasing their adherence to their pre-
scribedmedication and favouring a better perceived quality of life.Conclusions
Larger prospective studies are needed on adolescent liver trans-
plant recipients and on their transition to adulthood. There is still
a shortage of research on the risk factors, predictors, andmeasures
needed for adolescents before and after liver transplantation.
Many of the complications of liver transplantation relate to
the need for immunosuppression and adolescents may be at
greater risk of developing an altered glucose metabolism,
increased serum lipid levels, high blood pressure, poor renal
function, and cancer [81].
The greatest differences between transplanted adolescents
and the healthy population are reportedly in terms of school per-
formance. It is not clear, however, whether this relates to devel-
opmental delays or learning disabilities. Absences from school
due to illness or visits to doctors may also have a role, of course
[82].
For many young transplant recipients who have little or no
recollection of their surgery, the conventional metrics of trans-
plant success, e.g. patient and graft survival, or the absence of
complications, do not count in the same way as in adults [83].
Research is also needed on speciﬁc factors relating to non-adher-
ence after liver transplantation. Recommendations are needed on
how to manage this population of liver transplant recipients in
order to further improve their outcome by reducing the risk of
graft loss and other medical complications.Conﬂict of interest
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